CUTANEOUS T CELL LYMPHOMA (CTCL)
Clinical trials for CUTANEOUS T CELL LYMPHOMA (CTCL) explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS T CELL LYMPHOMA (CTCL) trials appear
Sign up with your email to follow new studies for CUTANEOUS T CELL LYMPHOMA (CTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New strategy aims to stop deadly skin cancer from coming back
Disease control Not yet recruitingThis study tests if giving the drug brentuximab vedotin as a preventive treatment after a stem cell transplant can stop an aggressive type of skin cancer (CTCL) from returning. It will involve 84 adults whose cancer had responded to prior treatments but is at high risk of relapse…
Matched conditions: CUTANEOUS T CELL LYMPHOMA (CTCL)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Experimental drug targets rare skin cancer in First-Ever human test
Disease control Not yet recruitingThis is the first-ever human trial of an experimental antibody called DT-7012 for patients with advanced cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. The study aims to find a safe dose and check for early signs that the drug might help control the disease in 30 a…
Matched conditions: CUTANEOUS T CELL LYMPHOMA (CTCL)
Phase: EARLY_PHASE1 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC